SSTR2 and neuroendocrine neoplasm: The evaluation of SSTR2 overexpression correlates positively with the existence and localization of the primary tumor and distant metastases.3 Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lutetium (Lu)-oxodotreotide (Lutathera®; Advanced Accelerators Applications AAA, Novartis) is indicated for the treatment of inoperable or metastatic, progressive, well-differentiated gastroenteropancreatic neuroendocrine tumors expressing SSTR2 in adults.